[ad_1]
Merck’s stock rallied into record territory Wednesday, after the drug giant’s treatment for pulmonary arterial hypertension, Winrevair, was approved by the U.S. Food and Drug Administration.
[ad_2]
Source link
[ad_1]
Merck’s stock rallied into record territory Wednesday, after the drug giant’s treatment for pulmonary arterial hypertension, Winrevair, was approved by the U.S. Food and Drug Administration.
[ad_2]
Source link
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More